Journal article
Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis
Glenn M Chertow, Geoffrey A Block, Ricardo Correa-Rotter, Tilman B Drueeke, Juergen Floege, William G Goodman, Charles A Herzog, Yumi Kubo, Gerard M London, Kenneth W Mahaffey, T Christian H Mix, Sharon M Moe, Marie-Louise Trotman, David C Wheeler, Patrick S Parfrey
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2012
Abstract
BACKGROUND: Disorders of mineral metabolism, including secondary hyperparathyroidism, are thought to contribute to extraskeletal (including vascular) calcification among patients with chronic kidney disease. It has been hypothesized that treatment with the calcimimetic agent cinacalcet might reduce the risk of death or nonfatal cardiovascular events in such patients. METHODS: In this clinical trial, we randomly assigned 3883 patients with moderate-to-severe secondary hyperparathyroidism (median level of intact parathyroid hormone, 693 pg per milliliter [10th to 90th percentile, 363 to 1694]) who were undergoing hemodialysis to receive either cinacalcet or placebo. All patients were eligible ..
View full abstractGrants
Funding Acknowledgements
Supported by Amgen.